Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Extensive-stage Small Cell Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 280 (planned)
- Started
- Apr 3, 2025
- Main results expected
- Sep 25, 2028
- Fully finished
- Sep 25, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase I: Incidence of dose-limiting toxicities (DLTs)
Measured over: 2 years
Phase I: Incidence of adverse events (AEs) and serious adverse events (SAEs)
Measured over: 2 years
Phase I: Number of participants with dose interruptions, reductions and discontinuations
Measured over: 2 years
Phase II: PFS rate at 6 months per local response evaluation criteria in solid tumors (RECIST) v1.1
Measured over: 6 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06726148 · record last updated 2026-08-27 · checked 2026-11-09 15:47 UTC